Glaxo Smith Kline’s (GSK) CEO, Sir Andrew Witty, announces further collaboration between the pharmaceutical industry and the developing world. Glaxo Smith Kline is one of the world’s leading research-based pharmaceutical and healthcare companies. Headquartered in the U.K, they work on developing innovative medicines and products that help millions of people around the world.
Andrew Witty, CEO, Glaxo Smith Kline with Aduwe Nosiante on a visit to Katine, Uganda Photograph: Martin Godwin
According to Witty, there will be a new shift in the pharmaceutical industry, where in CEOs of major pharmaceutical companies will work together in order to help end the misery of NTDs in the developing world. He states that these companies can “still compete like crazy in other areas, but there are areas where [they] can work sensibly together and [ultimately] allow [for them] to be successful in areas which have historically been very difficult.”
This means that the pharmaceutical industry will take on a greater commitment to eliminate NTDs in the developing world. They will work on creating easier access to drugs that other pharmaceutical companies do not have, for victims of NTDs. In essence, the ultimate objective for the pharmaceutical industry is to “discover more, better drugs for the future… and collaborat[e] with others to make it happen quicker.”
Check out this article to read more about Sir Andrew Witty’s take on NTDs.